scanX
Alkem Laboratories
add_icon

Alkem Laboratories

5,679.00
+3.50
(0.06%)
Market Cap
₹67,900.96 Cr
PE Ratio
28.29
Volume
61,858.00
Day High - Low
₹5,710.00 - ₹5,653.50
52W High-Low
₹5,868.00 - ₹4,491.65
ann
There are 1 new updates from the company1 hour ago
Viewcross
right
hide
Key Fundamentals
Add Ratio
split_icon_default
Market Cap
67,900.96 Cr
EPS
181.11
PB Ratio
5.11
Book Value
1,116.21
EBITDA
3,005.90
Dividend Yield
0.79 %
Industry
Healthcare
Sector
Pharmaceuticals
ROE Growth %
-
Debt to Equity
0.13
Analyst Rating and Forecast
- By Refinitiv from19 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+42.11 %
+42.11 %
Hold
Hold+36.84 %
+36.84 %
Sell
Sell+21.05 %
+21.05 %
Forecast For
Actual

Company News

View All News
Caret
neutral
Alkem Laboratories Senior VP Rakesh Tripathi Resigns Due to Personal CommitmentsToday
Mr. Rakesh Tripathi, Senior Vice President-Regulated Plant Operations at Alkem Laboratories, has resigned from his position effective December 8, 2025, citing personal and family reasons after 8.7 years with the company. The pharmaceutical company has acknowledged his valuable contributions during his tenure as Senior Management Personnel.
positive
Alkem Laboratories Appoints Prakash Ramnani to Senior Management Position2 days ago
Alkem Laboratories appointed Mr. Prakash Ramnani to a senior management position effective December 5, 2025. Ramnani brings over 25 years of experience in pharmaceutical manufacturing operations and technology transfer, with qualifications including M.Pharm and B.Pharm degrees.
negative
Alkem Laboratories Receives GST Demand Order Worth Rs. 54.94 Lakh2 days ago
Alkem Laboratories received a GST demand order from Assistant Commissioner, Central GST Division, Dehradun for Rs. 27.14 lakh along with penalty of Rs. 27.79 lakh for alleged excess ITC availment during F.Y. 2018-2019 to 2022-2023. The company disagrees with the order and plans to contest it, stating no material impact on financial or operational activities.
View more

Peer Comparison Compare Peers on Screener

Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
Sun Pharmaceutical
1,798.00
#1 4,31,400.43
40.68
#1 54,729.00
9.71
#1 10,980
2.89
63.65
Divis Laboratories
6,365.50
1,68,984.02
69.05
9,712.00
18.67
2,191
35.10
50.10
Torrent Pharmaceuticals
3,758.30
1,27,197.95
58.80
11,539.40
6.99
1,911
30.46
60.01
Cipla
1,507.70
1,21,785.08
22.73
28,409.50
7.12
5,291
3.71
48.01
Dr Reddys Laboratories
1,268.00
1,05,829.02
#1 18.15
33,741.20
16.73
5,725
-0.38
61.42
Lupin
2,078.20
94,922.72
21.34
22,909.50
13.74
3,306
#1 72.75
67.65
Zydus Life Science
927.30
93,308.08
18.56
23,511.00
18.55
4,615
34.60
40.18
Mankind Pharma
2,192.20
90,484.92
52.05
12,744.20
#1 20.90
2,007
-21.05
32.30
Aurobindo Pharma
1,192.60
69,266.40
20.70
32,345.60
9.43
3,484
3.81
58.88
Alkem Laboratories
5,679.00
#10 67,900.96
#6 28.29
#7 13,458.30
#10 3.70
#7 2,216
#5 10.98
53.12
Growth Rate
Revenue Growth
3.70 %
Net Income Growth
22.33 %
Cash Flow Change
-1.81 %
ROE
5.38 %
ROCE
4.61 %
EBITDA Margin (Avg.)
13.35 %

Quarterly Financial Results

Quarterly Financials
Mar 2015
Jun 2015
Sept 2015
Dec 2015
Mar 2016
Jun 2016
Sept 2016
Dec 2016
Mar 2017
Jun 2017
Sept 2017
Dec 2017
Mar 2018
Jun 2018
Sept 2018
Dec 2018
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Revenue
944
1,244
1,432
1,290
1,252
1,509
1,672
1,507
1,276
1,342
1,889
1,765
1,521
1,686
1,943
1,934
1,882
1,867
2,296
2,210
2,077
2,047
2,398
2,415
2,238
2,778
2,842
2,673
2,504
2,628
3,130
3,086
2,971
3,034
3,503
3,418
3,024
3,152
3,549
3,467
3,290
3,521
4,105
Expenses
777
1,001
1,127
1,052
993
1,210
1,328
1,214
1,102
1,218
1,405
1,381
1,389
1,455
1,555
1,613
1,619
1,585
1,811
1,729
1,746
1,470
1,762
1,789
1,901
2,139
2,176
2,121
2,162
2,373
2,626
2,442
2,652
2,579
2,751
2,668
2,546
2,423
2,662
2,615
2,753
2,632
3,080
EBITDA
167
242
306
238
260
299
344
294
174
124
485
384
132
231
388
321
263
282
484
481
331
577
636
626
337
640
666
552
343
255
505
644
319
455
752
750
478
729
887
852
537
889
1,025
Operating Profit %
13 %
16 %
17 %
17 %
14 %
18 %
19 %
18 %
12 %
7 %
24 %
21 %
7 %
12 %
19 %
16 %
13 %
14 %
20 %
21 %
15 %
26 %
25 %
23 %
13 %
22 %
22 %
19 %
13 %
8 %
15 %
20 %
9 %
13 %
20 %
20 %
13 %
20 %
22 %
23 %
12 %
22 %
23 %
Depreciation
18
21
26
23
24
23
26
26
26
31
35
38
40
43
46
48
57
56
56
60
81
67
70
69
69
71
73
78
83
76
77
78
78
72
74
70
83
81
79
85
113
88
94
Interest
17
23
20
19
10
10
12
12
11
13
18
15
10
16
16
15
7
16
18
17
14
17
18
13
11
13
12
11
17
27
25
27
29
30
30
26
27
29
28
36
28
30
35
Profit Before Tax
150
211
280
213
225
266
307
255
136
81
432
332
81
172
326
258
199
210
410
405
235
493
548
543
258
556
582
464
243
152
402
539
212
353
648
655
367
619
780
731
396
771
896
Tax
19
7
8
23
139
23
19
19
-1
17
105
152
15
35
66
53
28
23
29
15
44
70
66
80
9
76
23
-69
135
20
55
79
144
65
33
51
63
69
78
90
74
103
117
Net Profit
132
204
272
190
87
243
288
236
137
64
327
181
66
137
260
205
171
187
381
390
192
423
482
464
249
480
559
533
108
131
348
460
68
288
615
604
305
550
702
641
322
668
779
EPS in ₹
11.00
16.82
22.32
15.63
7.25
19.97
23.65
19.52
11.46
5.99
26.82
14.36
5.61
11.39
21.28
16.94
14.00
15.51
31.02
31.95
15.79
35.30
39.48
37.72
20.07
39.15
45.52
43.96
9.00
10.68
27.67
38.03
5.94
23.98
51.90
49.76
24.55
45.60
57.60
52.34
25.57
55.56
63.99
Above figures are in Rs. Crores

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total Assets
5,296
5,535
6,568
7,666
8,208
9,946
11,519
14,069
13,757
15,575
17,691
Fixed Assets
1,374
1,450
1,797
2,284
2,530
2,908
2,793
2,902
2,683
2,873
2,852
Current Assets
2,338
2,769
2,917
4,013
4,216
5,506
6,929
8,434
8,730
10,412
10,811
Capital Work in Progress
111
172
299
381
493
363
393
340
323
159
548
Investments
61
509
553
444
324
261
333
371
622
484
1,846
Other Assets
3,750
3,404
3,919
4,557
4,861
6,413
8,000
10,457
10,129
12,060
12,445
Total Liabilities
5,296
5,535
6,568
7,666
8,208
9,946
11,519
14,069
13,757
15,575
17,691
Current Liabilities
2,006
1,538
1,690
2,383
2,190
3,245
3,604
4,805
3,707
3,995
3,959
Non Current Liabilities
205
210
296
297
446
392
357
417
615
866
1,299
Total Equity
3,085
3,787
4,583
4,985
5,572
6,309
7,558
8,847
9,435
10,714
12,434
Reserve & Surplus
2,975
3,668
4,444
4,840
5,415
6,137
7,353
8,614
9,021
10,288
11,961
Share Capital
24
24
24
24
24
24
24
24
24
24
24
Above figures are in Rs. Crores

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Net Cash Flow
39
3
40
0
82
-73
-2
58
42
-208
-186
Investing Activities
-235
205
-294
-351
-318
-737
-995
-1,433
120
-1,011
-1,288
Operating Activities
326
726
471
266
780
585
1,265
1,111
1,683
1,948
1,913
Financing Activities
-52
-927
-138
85
-379
79
-272
380
-1,761
-1,145
-811
Above figures are in Rs. Crores

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Promoter
60.16 %
58.84 %
58.84 %
57.13 %
57.13 %
57.14 %
57.16 %
57.16 %
57.16 %
57.16 %
56.74 %
56.74 %
56.74 %
56.38 %
55.66 %
55.66 %
55.13 %
53.04 %
51.20 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
9.11 %
8.69 %
9.02 %
10.15 %
9.41 %
9.11 %
9.48 %
DIIs
12.97 %
14.28 %
13.78 %
13.76 %
13.93 %
13.88 %
15.26 %
16.44 %
16.69 %
15.43 %
17.64 %
14.94 %
15.63 %
18.57 %
19.21 %
18.01 %
19.42 %
21.80 %
21.93 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
21.75 %
21.70 %
21.15 %
22.85 %
22.63 %
22.33 %
22.28 %
21.74 %
21.44 %
20.61 %
19.36 %
18.60 %
18.31 %
16.15 %
15.84 %
15.90 %
15.77 %
15.69 %
17.18 %
Others
5.12 %
5.17 %
6.23 %
6.26 %
6.31 %
6.65 %
5.30 %
4.67 %
4.71 %
6.80 %
6.26 %
9.72 %
0.21 %
0.21 %
0.26 %
0.28 %
0.28 %
0.36 %
0.22 %
No of Share Holders
92,594
93,540
87,392
86,881
81,869
84,104
79,721
76,516
73,440
66,790
69,442
65,184
65,830
69,627
74,744
84,038
84,326
79,740
67,196

Dividend History

Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 15 13 16 25 30 34 50 40 45
Dividend Yield (%) 0.00 0.75 0.74 0.69 0.9 0.83 1.03 1.01 0.82 0.79

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
13 Feb 2021 DIVIDEND Dividend
₹ 25.00 /share
 11 Feb 2021 2,975.90 2,868.65
10 Aug 2021 DIVIDEND Dividend
₹ 5.00 /share
 09 Aug 2021 2,996.15 3,514.65
12 Feb 2022 DIVIDEND Dividend
₹ 30.00 /share
 10 Feb 2022 3,537.95 3,431.45
10 Aug 2022 DIVIDEND Dividend
₹ 4.00 /share
 08 Aug 2022 2,960.40 2,985.40
18 Feb 2023 DIVIDEND Dividend
₹ 25.00 /share
 17 Feb 2023 3,230.05 3,264.35
18 Feb 2023 DIVIDEND Dividend
₹ 15.00 /share
 17 Feb 2023 3,230.05 3,264.35
10 Aug 2023 DIVIDEND Dividend
₹ 10.00 /share
 10 Aug 2023 3,326.30 4,227.25
17 Feb 2024 DIVIDEND Dividend
₹ 35.00 /share
 16 Feb 2024 5,309.25 5,444.15
10 Aug 2024 DIVIDEND Dividend
₹ 5.00 /share
 09 Aug 2024 5,314.35 5,793.15
30 Aug 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
 30 Aug 2024 5,314.35 5,998.65
13 Nov 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 13 Nov 2024 5,796.25 5,501.35
07 Feb 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 07 Feb 2025 4,954.15 5,256.60
14 Feb 2025 DIVIDEND Dividend
₹ 37.00 /share
 14 Feb 2025 5,256.60 4,722.30
29 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 29 May 2025 5,290.35 5,265.65
08 Aug 2025 DIVIDEND Dividend
₹ 8.00 /share
 08 Aug 2025 5,265.65 4,878.10
12 Aug 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 12 Aug 2025 4,894.80 4,842.40
25 Aug 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
 25 Aug 2025 5,265.65 5,425.80
13 Nov 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 13 Nov 2025 5,550.35 5,765.05

Announcements

Announcement under Regulation 30 (LODR)-Change in Management1 hour ago
Announcement under Regulation 30 (LODR)-Change in Management2 days ago
Announcement under Regulation 30 (LODR)-Change in Management2 days ago
Disclosure Under Regulation 30 Of SEBI .3 days ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation4 days ago
Sustainability Report For Financial Year 2024-2025.5 days ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 25, 2025
GMP Inspection By Ministry Of Health Armenia At The Companys Manufacturing Facility Located At Sikkim IndiaNov 22, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 20, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptNov 19, 2025
Disclosure Under Regulation 30 Of SEBI LODR.Nov 18, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 14, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 14, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeNov 13, 2025
Closure of Trading WindowNov 13, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationNov 13, 2025
Unaudited Financial Results For The Quarter And Half Year Ended September 30 2025Nov 13, 2025
Board Meeting Outcome for Outcome Of Board Meeting Dated 13 November 2025Nov 13, 2025
EU GMP Inspection By German Health Authority At AlkemS Manufacturing Facility Located At Baddi IndiaNov 10, 2025
Announcement Under Regulation 30 Of SEBI LODR - Regulatory OrderNov 03, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media Release (Revised)Nov 03, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 03, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationOct 28, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationOct 28, 2025
Board Meeting Intimation for Notice Of Meeting Of The Board Of Directors Of The Company Scheduled To Be Held On 13Th November 2025Oct 23, 2025
Announcement Under Regulation 30 Of SEBI LODR - Regulatory OrderOct 01, 2025
Announcement Under Reg 30 (LODR)- Alkem Laboratories Limited Entered Into A Business Transfer Agreement With Alkem Wellness Limited A Wholly Owned Subsidiary Of The Company.Sep 26, 2025
Closure of Trading WindowSep 25, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementSep 25, 2025
Announcement Under Regulation 30 Of SEBI LODR - Regulatory OrderSep 24, 2025
Announcement Under Regulation 30 Of SEBI LODR - Regulatory OrderSep 22, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseSep 22, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 18, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 17, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 16, 2025
Announcement Under Reg 30 (LODR)- Cancellation Of Analyst / Institutional Investor Meeting Scheduled On Tuesday 09Th September 2025.Sep 09, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 08, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 03, 2025
Shareholder Meeting / Postal Ballot-Scrutinizers ReportAug 25, 2025
Shareholder Meeting / Postal Ballot-Outcome of AGMAug 25, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 22, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 19, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptAug 19, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeAug 12, 2025
Closure of Trading WindowAug 12, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationAug 12, 2025
Announcement under Regulation 30 (LODR)-AcquisitionAug 12, 2025
Results- Unaudited Financial Results For Quarter Ended June 30 2025Aug 12, 2025
Board Meeting Outcome for Outcome Of The BM Dated 12Th Aug 2025Aug 12, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 11, 2025

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
HDFC Mid Cap Fund Direct-Growth
0.00%
-1545839
-0.95%
-0.62%
SBI Large & Midcap Fund Direct Plan-Growth
0.00%
-1476712
-2.29%
-2.35%
ICICI Prudential Multi Asset Fund Direct-Growth
0.00%
-1450072
-1.11%
-1.20%
ICICI Prudential Large & Mid Cap Fund Direct Plan-Growth
0.00%
-1176641
-2.52%
-2.88%
Nippon India Growth Mid Cap Fund Direct- Growth
0.00%
-1163397
-1.55%
-1.60%
SBI Contra Direct Plan-Growth
0.00%
-1004007
-1.12%
-1.15%
DSP Midcap Direct Plan-Growth
0.00%
-748010
-2.10%
-2.12%
SBI Mid Cap Direct Plan-Growth
0.00%
-685892
-1.64%
-1.68%
ICICI Prudential Equity & Debt Fund Direct-Growth
0.00%
-510936
-0.59%
-0.60%
ICICI Prudential ELSS Tax Saver Direct Plan - Growth
0.00%
-499784
-1.85%
-2.02%
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct - Growth
0.00%
-465164
-3.98%
-4.05%
Axis Midcap Direct Plan-Growth
0.00%
-461670
-0.79%
-0.80%
DSP Flexi Cap Fund Direct Plan-Growth
0.00%
-441106
-1.99%
-2.01%
DSP Equity Opportunities Fund Direct Plan-Growth
0.00%
-440106
-1.47%
-1.51%
Nippon India Multi Cap Fund Direct-Growth
0.00%
-418576
-0.47%
-0.48%
HDFC Multi Cap Fund Direct - Growth
0.00%
-342618
-0.96%
-1.00%
UTI Mid Cap Fund Direct-Growth
0.00%
-340000
-1.55%
-1.69%
Kotak Arbitrage Fund Direct-Growth
0.00%
-325875
-0.25%
-0.30%
Nippon India Pharma Fund Direct-Growth
0.00%
-323678
-2.14%
-2.16%
HDFC Large and Mid Cap Fund Direct- Growth
0.00%
-312441
-0.60%
-0.63%
Tata Mid Cap Direct Plan-Growth
0.00%
-278911
-2.91%
-3.00%
Sundaram Mid Cap Fund Direct-Growth
0.00%
-275425
-1.15%
-1.19%
Franklin India Mid Cap Fund Direct-Growth
0.00%
-234107
-1.01%
-1.33%
Sundaram Large and Mid Cap Fund Direct-Growth
0.00%
-232400
-1.83%
-1.87%
ICICI Prudential India Opportunities Fund Direct - Growth
0.00%
-212496
-0.36%
-0.40%

Technical Indicators

RSI(14)
Neutral
53.12
ATR(14)
Volatile
102.82
STOCH(9,6)
Neutral
33.11
STOCH RSI(14)
Neutral
28.22
MACD(12,26)
Bearish
-12.85
ADX(14)
Weak Trend
12.92
UO(9)
Bearish
41.68
ROC(12)
Downtrend And Accelerating
-0.85
WillR(14)
Neutral
-55.74
Bearish
4
Neutral
4
Bullish
1

About Alkem Laboratories

Alkem Laboratories Limited is an Indian pharmaceutical company headquartered in Mumbai, with global operations. The company develops, manufactures, and sells pharmaceutical and nutraceutical products, including branded generics, generic drugs, active pharmaceutical ingredients (APIs), and nutraceuticals. It has a portfolio of over 800 brands in India and operates in more than 40 international markets, with the United States as its key focus. Alkem is ranked the fifth largest pharmaceutical company in India by domestic sales. The company's product offerings span various therapeutic areas such as anti-infective, cardiology, neurology, and gastroenterology. Alkem has invested in research and development, filing numerous Abbreviated New Drug Applications (ANDAs) with the US FDA. The company has multiple manufacturing facilities in India and abroad, and has expanded through acquisitions and subsidiaries in different countries.
Listing Date
23 Dec, 2015(9 Years, 15 days)
Website
https://www.alkemlabs.com
Chairperson NameBasudeo N Singh
raisewe are part of Raise Financial Services
Heart
built with love

for indians who love to invest & trade

Explore   |   Sitemap
Fundamental Screeners
Technical Screeners
Intraday Screeners
Price & Volume Screeners
Candlestick Screeners
Bullish Stocks Today
Bearish Stocks Today
Stocks Nearing 52W High & Low
Rise & Fall Stocks
Index
Sector
Stock Heatmap
Companies
Sensex Companies
Nifty 50 Companies
Nifty Next 50 Companies
Nifty Bank Companies
Finnifty Companies
Defence Stocks
Semi Conductor Stocks
Renewable Energy Stocks
AI Stocks
Cement Stocks
Penny Stocks
Multibagger Stocks
Breakout Stocks
Dividend Stocks
Large Cap Stocks
Mid Cap Stocks
Small Cap Stocks
About Scanx

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.
As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation. We plan to change that - a technology-led platform built for super traders and long term investors.

© 2025 Raise Securities Pvt. Ltd. All rights reserved.

Part of Raise Financial Services

Registered Office: Unit No. 2201, 22nd Floor, Gold Medal Avenue, S.V. Road, Beside Patel Petrol Pump, Piramal Nagar, Goregaon West, Mumbai - 400104